ado-trastuzumab emtansine (Kadcyla®)

Ado-trastuzumab emtansine (Kadcyla®; Genentech/Roche), as a single agent, is indicated for the treatment of patients with human epidermal growth factor 2 positive (HER2+) , metastatic breast cancer (MBC) who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: Received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.

Ado-trastuzumab emtansine is also used for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

United States


Join Our ADC Community

As a member of the ADC Directory, share your expertise, discover new solutions, network with peers and grow your business. Click on the link for more information.

Other FDA approved ADCs